Perioperative Glycemic Control for Patients Undergoing Coronary Artery Bypass Grafting
Coronary artery bypass grafting (CABG), as a gold standard treatment for coronary artery disease, has been widely adopted all around the world. Meanwhile, it’s also well known that diabetes is an independent risk factor for postoperative mortality. However, hyperglycemia often occurs perioperatively...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2022
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/81002 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Perioperative Glycemic Control for Patients Undergoing Coronary Artery Bypass Grafting
- Ivabradine Versus Beta-Blockers in Patients with Conduction Abnormalities or Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Grafting
- Perioperative Use of Impella 5.0/5.5 in High-Risk Coronary Artery Bypass Grafting
- Pharmacology of Arterial Grafts for Coronary Artery Bypass Surgery
- Treatment of Coronary Artery Bypass Graft Failure
- Clinical Follow-Up of Patients after Coronary Artery Bypass Grafting
- Exercise Training for Patients After Coronary Artery Bypass Grafting Surgery